An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence
Eugen Dhimolea,Ricardo de Matos Simoes,Dhvanir Kansara,Aziz Al'Khafaji,Juliette Bouyssou,Xiang Weng,Shruti Sharma,Joseline Raja,Pallavi Awate,Ryosuke Shirasaki,Huihui Tang,Brian J Glassner,Zhiyi Liu,Dong Gao,Jordan Bryan,Samantha Bender,Jennifer Roth,Michal Scheffer,Rinath Jeselsohn,Nathanael S Gray,Irene Georgakoudi,Francisca Vazquez,Aviad Tsherniak,Yu Chen,Alana Welm,Cihangir Duy,Ari Melnick,Boris Bartholdy,Myles Brown,Aedin C Culhane,Constantine S Mitsiades,Aziz Al’Khafaji,Brian J. Glassner,Nathanael S. Gray,Aedin C. Culhane,Constantine S. Mitsiades
DOI: https://doi.org/10.1016/j.ccell.2020.12.002
IF: 50.3
2021-02-01
Cancer Cell
Abstract:Treatment-persistent residual tumors impede curative cancer therapy. To understand this cancer cell state we generated models of treatment persistence that simulate the residual tumors. We observe that treatment-persistent tumor cells in organoids, xenografts, and cancer patients adopt a distinct and reversible transcriptional program resembling that of embryonic diapause, a dormant stage of suspended development triggered by stress and associated with suppressed Myc activity and overall biosynthesis. In cancer cells, depleting Myc or inhibiting Brd4, a Myc transcriptional co-activator, attenuates drug cytotoxicity through a dormant diapause-like adaptation with reduced apoptotic priming. Conversely, inducible Myc upregulation enhances acute chemotherapeutic activity. Maintaining residual cells in dormancy after chemotherapy by inhibiting Myc activity or interfering with the diapause-like adaptation by inhibiting cyclin-dependent kinase 9 represent potential therapeutic strategies against chemotherapy-persistent tumor cells. Our study demonstrates that cancer co-opts a mechanism similar to diapause with adaptive inactivation of Myc to persist during treatment.
oncology,cell biology